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Abstract
Gastrin and cholecystokinin (CCK) are hormones released from endocrine cells 
in the antral stomach (gastrin), the duodenum, and the jejunum (CCK). Recent re-
ports, based on secretion experiments in an enteroendocrine cell line (NCI-H716) 
and gastrin receptor expression in proglucagon-expressing cells from the rat colon, 
suggested that gastrin could be a regulator of glucagon-like peptide-1 (GLP-1) secre-
tion. To investigate these findings, we studied the acute effects of CCK-8 (a CCK1/
CCK2 (gastrin) receptor agonist) and gastrin-17 (a CCK2(gastrin) receptor agonist) 
in robust ex vivo models: the isolated perfused rat small intestine and the isolated 
perfused rat colon. Small intestines from Wistar rats (n = 6), were perfused intraar-
terially over 80 min. During the perfusion, CCK (1 nmol/L) and gastrin (1 nmol/L) 
were infused over 10-min periods separated by washout/baseline periods. Colons 
from Wistar rats (n  =  6) were perfused intraarterially over 100  min. During the 
perfusion, CCK (1  nmol/L), vasoactive intestinal peptide (VIP) (10  nmol/L), and 
glucose-dependent insulinotropic polypeptide (GIP) (1 nmol/L) were infused over 
10-min periods separated by washout/baseline periods. In the perfused rat small in-
testines neither CCK nor gastrin stimulated the release of GLP-1 or neurotensin. In 
the perfused rat colon, neither CCK or VIP stimulated GLP-1 or peptide YY (PYY) 
release, but GIP stimulated both GLP-1 and PYY release. In both sets of experi-
ments, bombesin, a gastrin-releasing peptide analog, served as a positive control. Our 
findings do not support the suggestion that gastrin or CCK participate in the acute 
regulation of intestinal GLP-1 secretion, but that GIP may play a role in the regula-
tion of hormone secretion from the colon.
K E Y W O R D S
bombesin, CCK, cholecystokinin, colon, ex vivo, gastrin, GIP, GLP-1, glucagon-like peptide-1, glucose-
dependent insulinotropic polypeptide, hormones, isolated perfused colon, isolated perfused small 
intestine, neurotensin, peptide YY, PYY, rat, secretion, vasoactive intestinal peptide, VIP
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1 |  INTRODUCTION
Gastrin and cholecystokinin (CCK) are gastrointestinal hor-
mones released from endocrine cells in the antral stomach 
(gastrin) and the duodenum and jejunum (CCK) (Rehfeld, 
1998). CCK has also been identified in neurons innervat-
ing the small intestine and colon (Larsson & Rehfeld, 1979; 
Schultzberg et al., 1980).
Recently, it has been suggested, based on gastrin recep-
tor expression in a human enteroendocrine cell line (NCI-
H716) and in proglucagon-expressing cells harvested from 
rat colon tissue, that gastrin, released from the proximal 
gastrointestinal tract is involved in the regulation of the 
more distal gut hormone glucagon-like peptide-1 (GLP-1) 
(Cao, Cao, & Liu, 2015). CCK-2 (gastrin) receptors were 
found to be expressed in NCI-H716 cells (mRNA, protein, 
and immunohistochemistry), a human colon epithelial cell 
line, and in rat colonic L-cells (immunohistochemistry). 
In NCI-H716 cells, the gastrin concentration necessary 
to elicit GLP-1 release over 2 hr ranged between 10–8 and 
10–6 M gastrin.
We are not aware of reports of the effects of gastrin on 
gut hormone secretions in vivo (humans or animals) or in 
ex vivo animal models. Meanwhile, gastrin-releasing pep-
tide and a non-mammalian homolog bombesin, are power-
ful stimulants of gut hormone release (Roberge, Gronau, & 
Brubaker, 1996).
A potential role for CCK in the regulation of dis-
tal gut hormone secretion has previously been inves-
tigated using both in vivo and ex vivo models. Thus, in 
the isolated perfused rat small intestine (ileum), CCK-8 
at a dose of 50  pmol/L did not stimulate GLP-1 or NT 
secretion (Dumoulin, Dakka, Plaisancie, Chayvialle, 
& Cuber, 1995). In the perfused isolated rat colon, the 
same CCK dose (50  pmol/L) increased PYY secretion 
(apparent after 15  min of perfusion), but increasing the 
dose to 250 pmol/L did not further increase PYY secre-
tion (Plaisancié, Bernard, Bernard, Chayvialle, & Cuber, 
1995). In the same study, intraarterial GIP increased PYY 
secretion, while VIP did not. In subsequent experiments, 
employing the isolated rat colon, CCK infusion was asso-
ciated with increased PYY secretion (Ko et al., 2011) and 
increased colonic motility.
Incubation of fetal rat intestinal cell cultures with CCK 
(10–12 to 10–6 M) did not increase GLP-1 concentrations in 
the medium (Brubaker & Brubaker, 1991) and infusion of 
CCK (16 ng bolus and 25 ng/h) into anesthetized rats did 
not stimulate the secretion of GLP-1 (Roberge & Brubaker, 
1991). Meanwhile, in isolated perfused porcine small intes-
tine, CCK at a concentration of 1 nmol/L (~100–500 times 
normal postprandial plasma concentrations) increased 
GLP-1 concentrations in the venous effluent, whereas, 
lower (0.1 nmol/L) and higher (10 nmol/L) concentrations 
of CCK did not stimulate GLP-1 secretion (Hansen & 
Holst, 2002).
In human studies evaluating the effect of CCK infusions 
on gastrointestinal hormone release (Brennan et al., 2007; 
Rohde et al., 2016), it was not possible to discriminate be-
tween direct effects of CCK on gut endocrine cells and in-
direct effects elicited by, for example, CCK-stimulated bile 
release, but CCK infusions, giving rise to near complete 
gallbladder emptying, were associated with increased plasma 
GLP-1 (Rohde et al., 2016). Bile acids should be considered 
as a potential mediator as they stimulate gut hormone se-
cretions ex vivo (Brighton et al., 2015; Christiansen et al., 
2019; Kuhre et al., 2018; Plaisancié, Dumoulin, Chayvialle, 
& Cuber, 1995) and in humans under physiologically relevant 
conditions (Meyer-Gerspach et al., 2013; Nielsen et al., 2017; 
Wu et al., 2013).
To investigate the recent findings regarding gas-
trin-stimulated GLP-1 secretion(Cao et al., 2015), we 
tested whether gastrin and CCK at supra-physiological 
levels (the same concentrations that was reported to stim-
ulate GLP-1 secretion in porcine intestines) would elicit 
secretion of GLP-1, PYY, and neurotensin, gut peptides re-
leased from different enteroendocrine cell subpopulations 
(L-cells (GLP-1 and PYY, small intestine and colon) and 
N-cells (neurotensin, distal small intestine), respectively). 
We included CCK recognizing that CCK at high concen-
trations is able to activate not only the CCK-1 receptor but 
also the gastrin (CCK-2) receptor due to structural sim-
ilarities between gastrin and CCK. In the colon experi-
ments, we included vasoactive intestinal peptide (VIP) 
and glucose-dependent insulinotropic polypeptide (GIP) 
because these peptides have been suggested to be hormone 
secretagogues in the colon (Plaisancié, Bernard, et al., 
1995). For our experiments, we relied on isolated perfused 
preparations of rat small intestine and colon, previously 
demonstrated to respond adequately to known stimuli of 
gut hormone secretion.
2 |  METHODS
2.1 | Animals
Studies were performed with permission from the Danish 
Animal Experiments Inspectorate and the local animal 
studies regulatory body in accordance with the guidelines 
of the Danish legislation governing animal experimenta-
tion (1987).
Male Wistar rats (small intestinal perfusions, mean 
(SD) = 277 (17) g), colon perfusions (265 (11) g), were ob-
tained from Janvier labs (Le Genest-Saint-Isle, housed 2–4 
rats per cage and kept on a 12:12  hr light/dark cycle with 
ad libitum access to standard chow and water in the animal 
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house at the Faculty of Health and Medical Sciences, The 
University of Copenhagen.
2.2 | Intestinal perfusions
On the experimental day, animals (non-fasted) were an-
esthetized with a subcutaneous Hypnorm/Midazolam 
injection (doses 0.0158 mg fentanyl citrate + 0.5 mg fluani-
sone + 0.25 mg midazolam/100 g) and placed on a heating 
plate (37°C).
2.2.1 | Small intestinal perfusions
The abdomen was opened and the entire large intestine and 
the distal half of the small intestine carefully removed, leav-
ing 30(2) cm of the upper small intestine in situ. A plastic 
tube was inserted into the oral opening of the small intestinal 
lumen and the intestinal luminal content was gently removed 
with isotonic saline (room temperature). The small intestinal 
lumen was perfused with saline at a steady flow of 0.25 ml/
min. A catheter was placed in the superior mesenteric artery 
and the intestine was perfused at a rate of 7.5 ml/min with a 
gassed perfusion buffer (95% O2/5% CO2) heated to 37°C. 
(Modvig, Kuhre, & Holst, 2019).
2.2.2 | Colon perfusions
The abdomen was opened and the colon was isolated by 
ligating the vessels to the small intestine, cecum, spleen, 
stomach, kidneys as well as the celiac artery. This allowed 
the vascular isolation of 10.8 (0.3) cm of the colon, cor-
responding to a segment spanning from the most proximal 
part of the colon to the part just proximal to the entry of 
the inferior mesenteric artery. A plastic tube was inserted 
into the oral opening of the colonic lumen and the luminal 
content gently removed with isotonic saline (room tem-
perature). The colonic lumen was perfused with saline at a 
steady flow of 0.15 ml/min. A catheter was inserted into the 
abdominal aorta, which was ligated proximally and distally 
to the outlet of the superior mesenteric artery, and perfu-
sion was started at a rate of 3 ml/min with a gassed perfu-
sion buffer (95% O2/5% CO2) heated to 37°C (Christiansen 
et al., 2018, 2019).
When perfusion had been established, animals were sac-
rificed by cardiac perforation and the preparation allowed 
to equilibrate for ~30  min before samples were collected. 
The effluent perfusion buffer was collected over 1-min pe-
riods from a portal vein catheter into low adsorbent tubes 
(minisorb, Nunc), which were placed immediately into ice 
and then stored at −20°C until analyses.
2.3 | Perfusion buffer
The buffer consisted of a Krebs-Ringer bicarbonate buffer 
supplemented with 0.1% BSA (albumin fraction V; Merck, 
cat. no. 1.12018.0500, Ballerup, Denmark), 3.5  mmol/L 
glucose, 5% dextran T-70 (to balance oncotic pressure; 
Pharmacosmos, Holbaek, Denmark), 10 µmol/L 3-Isobutyl-
1-methylxanthine (IBMX) (Sigma-Aldrich, cat. no. 5,879), 
2 ml/L of Vamin (cat. no. 11338; Fresenius Kabi, Uppsala, 
Sweden), and 5 mmol/L pyruvate, fumarate, and glutamate. 
pH was adjusted with hydrochloric acid to 7.4–7.5.
2.4 | Peptide infusions
CCK-8, gastrin-17 (provided by JF Rehfeld), VIP (Bachem 
cat.no. H-3775), and rat GIP (provided by Mette Rosenkilde) 
were dissolved in water with 1% human serum albumin, and 
aliquots were prepared for each experiment. On the day of 
experiments, vials were thawed and infusions prepared by 
diluting the peptide aliquots with the perfusion buffer de-
scribed above. Bombesin (BBS) (Bachem, cat.no. H-2155) 
was dissolved in water with 1% human serum albumin and 
further diluted in perfusion buffer to reach a final perfusate 
concentration of 10 nmol/L.
2.5 | Peptide hormone analyses
Gut hormones were measured using in-house radioim-
munoassays: total GLP-1 was measured using anti-serum 
no. 89390, directed against the C-terminus of GLP-1 
(Orskov, Rabenhoj, Wettergren, Kofod, & Holst, 1994). 
Total Neurotensin was measured using antiserum no 
3D97 (Kuhre, Bechmann, Wewer Albrechtsen, Hartmann, 
& Holst, 2015). Total PYY immunoreactivity (PYY1–
36  +  PYY3–36) was measured with a porcine antiserum 
(cat. no T-4093; Bachem) (Toräng, Veedfald, Rosenkilde, 
Hartmann, & Holst, 2015).
2.6 | Statistics
Hormone responses (fmol/L  ×  min) were determined as 
the areas under the curve (AUC) for the 10-min preced-
ing and during infusions (5 min for BBS infusions) using 
the trapezoidal rule. Total hormone outputs were calcu-
lated by multiplying hormone responses with the perfusion 
flow rates—small intestine perfusions (0.0075 L/min) and 
colon perfusions (0.003 L/min). If repeated measurements 
(RM) one-way analysis of variance (ANOVA) resulted 
in significant differences (p  <  .05), the pre-stimulus and 
during stimulus outputs were compared with Bonferroni 
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corrections (for small intestinal perfusions (pre CCK vs. 
CCK, pre gastrin vs. gastrin, pre BBS vs. BBS) and for 
colon perfusions (pre CCK vs. CCK, pre VIP vs. VIP, pre 
GIP vs. GIP). Data are means with standard errors of the 
means (SEM) unless otherwise stated. All statistical analy-
ses were performed with GraphPad Prism 8.0 for Mac (San 
Diego, CA, USA).
3 |  RESULTS
3.1 | Small intestinal perfusions
NT concentrations over the course of the experiment were 
analyzed by one-way ANOVA (p = .0008) (Figure 1a and b). 
This result allowed post hoc comparisons. Neither CCK nor 
gastrin increased neurotensin secretion (p  =  .99), but BBS 
did (p = .003) (Figure 1b).
GLP-1 concentrations over the course of the experiment 
were analyzed by one-way ANOVA (p = .0001) (Figure 1c 
and d), which allowed post hoc comparisons. Neither CCK 
nor gastrin increased neurotensin secretion (p  =  .99), but 
BBS did (p < .0001) (Figure 1d).
3.2 | Colon perfusions
GLP-1 concentrations over the course of the experiments 
were analyzed by one-way ANOVA (p =  .011) (Figure 2a 
and b). This result allowed post hoc comparisons. CCK did 
not increase GLP-1 secretion (p  =  .99). Neither did VIP 
(p = .98). However, GIP (p < .001) and BBS (p = .01) in-
creased GLP-1 secretion (Figure 2b).
PYY concentrations over the course of the experiments 
were analyzed by one-way ANOVA ( p =  .001) (Figure 2c 
and d). This result allowed post hoc comparisons. Neither 
F I G U R E  1  Neurotensin (a) and Glucagon-like peptide-1 (GLP-1) (c) output (fmol/min) in the venous effluent from the isolated perfused 
rat small intestine (Wistar, n = 6). After a 10-min baseline, cholecystokinin (CCK) was infused intraarterially (1 nmol/L, 10 min). After a 20-min 
washout, gastrin was infused intraarterially (1 nmol/L, 10 min). Finally, bombesin (BBS, a gastrin-releasing peptide analog) was infused over 5 min 
as a positive control. Hormone outputs) for neurotensin (b) and GLP-1 (D). Filled circles represent areas hormone output over 10 min for individual 
rats, (5 min periods for BBS). Data are means with standard errors of the mean. Post hoc comparisons were made by one-way analyses of variance 
(ANOVA) with Bonferroni corrections
A
C D
B
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CCK nor VIP increased PYY secretion (p = .99). Both GIP 
(p  =  .016) and BBS stimulated PYY release (p  =  .006) 
(Figure 2d).
Neurotensin concentrations were also analyzed, but 
concentrations were all lower than the detection limit 
(1–2  pmol/L) even during bombesin stimulations (data not 
shown).
4 |  DISCUSSION
We did not find any stimulatory effect of high concentrations 
of CCK or gastrin on the release of GLP-1 and neurotensin 
from the rat small intestine. Neither could we find any stimu-
latory effect of CCK and VIP on GLP-1 and PYY secretion 
from the rat colon. However, GIP stimulated GLP-1 and 
PYY release from the perfused rat colon.
The possibility that hormones released from the proximal 
gut could participate in the regulation of gut hormones se-
creted from the distal gut has been extensively investigated 
in animal models with particular focus given to the potential 
effect of CCK.
The motivation for this study was the finding that gastrin 
(CCK2) receptors had been identified in a human enteroen-
docrine cancer cell line (NCI-H716) and that gastrin given 
at high (10–1,000 nmol/L) supraphysiologic doses increased 
GLP-1 concentrations in the medium of an enteroendocrine 
cancer cell line over 2  hr. Gastrin receptors were also re-
ported to be located on GLP-1 producing cells from the rat 
colon, but secretion experiments using tissue from the colon 
were not performed (Cao et al., 2015).
In earlier studies, CCK has been reported to stimulate 
GLP-1 secretion (Hansen & Holst, 2002; Ko et al., 2011; 
Plaisancié, Bernard, et al., 1995). However, in two of these 
F I G U R E  2  Glucagon-like peptide-1 (GLP-1) (a) and peptide YY (PYY) (c) output (fmol/min) in the venous effluent from the isolated 
perfused rat colon (Wistar, n = 6). After a 10-min baseline, Cholecystokinin (CCK) was infused intraarterially (1 nmol/L, 10 min). After a 15-
min washout, vasoactive intestinal peptide (VIP) was infused intraarterially (10 nmol/L, 10 min), after a 15-min washout glucose-dependent 
insulinotropic polypeptide (GIP) was infused intraarterially (1 nmol/L, 10 min). Finally, Bombesin (BBS, a gastrin-releasing peptide analog) was 
infused over 5 min as a positive control. Hormone outputs for GLP-1 (b) and PYY-1 (d). Filled circles hormone outputs over 10-min periods for 
individual rats, (5-min periods for BBS). Data are means with standard errors of the mean. Post hoc comparisons were made by one-way analyses 
of variance (ANOVA) with Bonferroni corrections
A
C D
B
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studies the stimulatory effects of CCK were modest and not 
reproducible with higher CCK doses.
Intraarterial VIP has previously been tested in the isolated 
perfused rat small intestinal model, and in that intestinal seg-
ment VIP weakly elicited GLP-1 secretion (Herrmann-Rinke, 
Vöge, Hess, & Göke, 1995). In our experiments, VIP did not 
elicit GLP-1 or PYY secretion from the isolated perfused 
colon.
Intravenous administration of GIP in rats has been re-
ported to elicit GLP-1 secretion, albeit the rise in plasma 
GLP-1 was not apparent until 20 min after the initiation of 
the GIP administration (Roberge & Brubaker, 1993). In the 
perfused rat ileum, intraarterial GIP has also been reported to 
stimulate GLP-1 secretion from the isolated perfused ileum 
(Herrmann-Rinke et al., 1995). We find that also in the colon 
intraarterial GIP stimulates GLP-1 and PYY secretion.
Our study has limitations. We did not use doses higher 
than 1 nmol/L of CCK, gastrin, and GIP (10 nmol/L of VIP 
was used to emulate its release from enteric nerves). Our 
study aimed to determine whether gastrin and CCK would 
impact GLP-1 and neurotensin secretion via the endocrine 
pathway under physiological conditions. To be sure not to 
overlook an effect we employed supraphysiological con-
centrations. As all the stimuli employed are peptides (not 
small molecules) acting via G-protein coupled receptors, 
we do not expect off target effects—at the modestly sup-
raphysiological doses employed. We did not evaluate the 
bioactivity of the peptides employed independently from 
the perfusion studies, but all peptides were procured from 
trusted sources, their purity and structural integrity were 
controlled in our laboratories (CCK and gastrin) or by the 
manufacturers (GIP, VIP, BBS) and were prepared fresh for 
each perfusion, which would limit any degradation to min-
imal spontaneous hydrolysis. Plasma CCK concentrations 
would under normal circumstances be about 50–200 times 
lower than the employed dose. Peak plasma gastrin con-
centrations after liquid and solid meals would be expected 
to be about 20  pmol/L (Sonne, Rehfeld, Holst, Vilsbøll, 
& Knop, 2014) and 20–40 pmol/L, respectively (Hornnes 
et al., 1980; Rasmussen et al., 1997), that is, ~25–50 times 
lower than the dose used in our experiments. During treat-
ment with proton pump inhibitors gastrin concentrations 
increase ~2–4 fold, but even under these circumstances the 
gastrin concentration used in our perfusions would still be 
about 8–10 fold higher than circulating concentration of 
gastrin (Obszynska et al., 2010; Rasmussen et al., 1997).
We used a GIP dose only 10–15 fold higher than what 
would be observed in individuals with rapid gastric empty-
ing and Roux-en-Y gastric bypass (Jørgensen et al., 2013; 
Plamboeck et al., 2013). Thus, given the effect of GIP ob-
served in the perfused colon it cannot be ruled out that GIP 
might be able to stimulate colonic gut hormone secretions in 
vivo.
5 |  CONCLUSION
We find that (1) Acute CCK1/CCK2 receptor agonism does 
not stimulate GLP-1 or neurotensin secretion from isolated 
perfused rat small intestine and (2) Acute CCK1/CCK2 re-
ceptor agonism does not stimulate GLP-1 and PYY secretion 
from the isolated perfused rat colon.
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